1243 - Radiation Modulates HER2 Expression and Trastuzumab Deruxtecan Response in HER2-Low Metastatic Breast Cancer
Presenter(s)
Q. Li1, G. Rather2, T. Nwachukwu3, C. Speers4, H. K. Perlow1, P. Vempati1, B. G. Haffty2, and T. Miller3; 1Department of Radiation Oncology, University Hospitals Cleveland Medical Center/ Seidman Cancer Center, Cleveland, OH, 2Rutgers Cancer Institute of New Jersey, Department of Radiation Oncology, New Brunswick, NJ, 3Department of Pathology, Case Western Reserve University, Cleveland, OH, 4University of Alabama at Birmingham, Department of Radiation Oncology,, Birmingham, AL
Purpose/Objective(s): Breast cancer brain metastases remain therapeutically challenging despite combination therapies. With the development of HER2 antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd), patients with low HER2 expression, who previously had limited response to traditional HER2-targeted therapy, have demonstrated responses to T-DXd, including activity in CNS. Response to HER2-targeted ADCs depends on tumor cell surface HER2 availability, which is dynamic and may be modulated by treatment. Prior studies have shown that radiation induces HER2 expression and may promote radioresistance. Instead of viewing this as detrimental, we hypothesized that low-dose RT increases tumor cell surface HER2 expression in HER2-low breast cancer, which may enhance T-DXd internalization and therapeutic efficacy in CNS disease.
Materials/Methods: Mechanistic studies were performed in HER2-low breast cancer cell lines (T47D and MDA-MB-231), 5 patient-derived brain metastasis organoids with different levels of HER2, and orthotopic murine models. Different dose and fractionation regimens were evaluated for effects on HER2 membrane expression, ADC internalization, and cytotoxic response. HER2 surface expression was quantified by flow cytometry and immunohistochemistry. In vivo HER2 modulation was assessed in orthotopic tumors following RT. RNA sequencing characterized radiation-induced signaling and immune alterations across RT doses. To assess clinical relevance, a retrospective cohort of 13 patients treated with T-DXd was analyzed based on receipt of RT within 3 months prior to therapy. CNS progression-free survival (CNS-PFS) was evaluated using Kaplan-Meier analysis.
Results: Low-dose RT (3.33 Gy × 4) significantly increased HER2 membrane expression in HER2-low cell lines and patient-derived brain metastasis organoids when compared to no RT or high-dose RT (8Gyx3 or 20Gyx1). Orthotopic tumors demonstrated HER2 upregulation following RT, consistent with in vitro findings. Radiation enhanced T-DXd internalization and cytotoxic efficacy in HER2-low models. Transcriptomic analyses showed that low-dose radiation activated oncogenic pathways associated with HER2 regulation and generated distinct immune signatures compared with higher-dose regimens, suggesting dose-dependent biologic reprogramming. Clinically, patients receiving RT within 3 months prior to T-DXd exhibited improved CNS-PFS compared with those without recent RT (median 13.4 vs 2.6 months, p=0.0212; HR 0.33, 95% CI 0.07–1.66), suggesting recent RT may enhance T-DXd efficacy and CNS control.
Conclusion: Low-dose RT reprograms HER2-low breast cancer brain metastases by increasing tumor surface HER2 expression and enhancing ADC internalization. These findings support a radiation-priming strategy to optimize T-DXd efficacy in CNS disease. Prospective studies are warranted to define optimal radiation dosing and sequencing to improve intracranial control in HER2-low breast cancer.